In:
Oncology, S. Karger AG, Vol. 92, No. 2 ( 2017), p. 101-108
Abstract:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma (ESCC) requires reassessment. We have conducted a trial aiming at the comparison between DCF and ACF concerning perioperative adverse events. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Patients were randomly assigned to receive either DCF [docetaxel 70 mg/m 〈 sup 〉 2 〈 /sup 〉 , cisplatin 70 mg/m 〈 sup 〉 2 〈 /sup 〉 on day 1, and 5-fluorouracil (5-FU) 700 mg/m 〈 sup 〉 2 〈 /sup 〉 for 5 days] every 3 weeks or ACF (adriamycin 35 mg/m 〈 sup 〉 2 〈 /sup 〉 , cisplatin 70 mg/m 〈 sup 〉 2 〈 /sup 〉 on day 1, and 5-FU 700 mg/m 〈 sup 〉 2 〈 /sup 〉 for 7 days) every 4 weeks. Each group consisted of 81 patients. Two cycles of preoperative chemotherapy were planned, after which patients underwent subtotal esophagectomy via a right thoracotomy with lymphadenectomy. Chemotherapy- and surgery-related adverse effects were assessed. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Grade 3-4 neutropenia and febrile neutropenia occurred in 90 and 39% of patients, respectively, in the DCF group compared with 69 and 17% of patients, respectively, in the ACF group ( 〈 i 〉 p 〈 /i 〉 〈 0.01). Perioperative complications did not differ significantly between the groups. The overall response rates of DCF and ACF were 61 and 40%, respectively, while the histopathological complete responses were 15 and 3%, respectively ( 〈 i 〉 p 〈 /i 〉 〈 0.01). 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 The DCF and ACF regimens were found to be equally feasible in patients with resectable advanced ESCC; however, DCF delivered an antitumor effect and therefore potentially improved the long-term outcomes.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2017
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink
